 Yeah, you know, forgetting the assets we're acquiring, the core asset TCB 0-0-8 is going gangbusters. So post the MHRE approving and accepting our amendment, we've restarted the trial. We expect to dose the first patient in the second cohort, so the subsequent 14 patients, probably before the end of May, which means we're on track to announce data in that trial in Q4 of this year at the latest.